Teva Pharmaceutical Set to Join Premier US Russell 1000 Stock Index

Teva Pharmaceutical Industries is slated to join the benchmark Russell 1000 Index following its recent transition to direct New York Stock Exchange trading, boosting potential institutional demand.

Teva Pharmaceutical Set to Join Premier US Russell 1000 Stock Index
Photo: Unsplash / Oren Elbaz

Teva Pharmaceutical Industries is set to join the benchmark Russell 1000 Index, marking a major milestone following its structural shift to a direct New York Stock Exchange listing. Two months ago, the pharmaceutical company completed a technical transition from American Depositary Shares to direct common stock trading, a move executives anticipated would broaden its global investor base and open doors to premier equity indices.

London Stock Exchange Group, which manages the Russell indices, included Teva in its preliminary reconstitution list for the Russell 1000, tracking the 1,000 largest US capitalization equities. As of December 2025, approximately $12.5 trillion in assets were benchmarked against the Russell indices, with the collective market capitalization of index constituents reaching about $77.5 trillion.

Index reconstitutions occur semi-annually in June and December, and inclusion typically generates substantial passive demand for a company's shares. Alongside Teva, the upcoming index additions span several sectors, including technology and healthcare additions such as NXP and Shopify, alongside industrial, consumer, financial, real estate, and utility firms.

The Russell 1000 features prominent global giants including Apple, Nvidia, Microsoft, Alphabet, Amazon, and SpaceX, with Eli Lilly currently standing as the largest pharmaceutical company in the index. Teva presently maintains a market capitalization of $49.7 billion.

Related News